Effects of local anesthetics on Na+ channels containing the equine hyperkalemic periodic paralysis mutation.
We examined the ability of local anesthetics to correct altered inactivation properties of rat skeletal muscle Na+ channels containing the equine hyperkalemic periodic paralysis (eqHPP) mutation when expressed in Xenopus oocytes. Increased time constants of current decay in eqHPP channels compared with wild-type channels were restored by 1 mM benzocaine but were not altered by lidocaine or mexiletine. Inactivation curves, which were determined by measuring the dependence of the relative peak current amplitude after depolarization to -10 mV on conditioning prepulse voltages, could be shifted in eqHPP channels back toward that observed for wild-type (WT) channels using selected concentrations of benzocaine, lidocaine, and mexiletine. Recovery from inactivation at -80 mV (50-ms conditioning pulse) in eqHPP channels followed a monoexponential time course and was markedly accelerated compared with wild-type channels (tauWT = 10.8 +/- 0.9 ms; taueqHPP = 2.9 +/- 0.4 ms). Benzocaine slowed the time course of recovery (taueqHPP,ben = 9.6 +/- 0.4 ms at 1 mM) in a concentration-dependent manner. In contrast, the recovery from inactivation with lidocaine and mexiletine had a fast component (taufast,lid = 3.2 +/- 0.2 ms; taufast,mex = 3.1 +/- 0.2 ms), which was identical to the recovery in eqHPP channels without drug, and a slow component (tauslow,lid = 1,688 +/- 180 ms; tauslow,mex = 2,323 +/- 328 ms). The time constant of the slow component of the recovery from inactivation was independent of the drug concentration, whereas the fraction of current recovering slowly depended on drug concentrations and conditioning pulse durations. Our results show that local anesthetics are generally incapable of fully restoring normal WT behavior in inactivation-deficient eqHPP channels.
Sah
R L
RL
Department of Medicine, University of Toronto, Toronto, Ontario, Canada M5G 1L7.
Tsushima
R G
RG
Backx
P H
PH
D000779:Anesthetics, Local / Q000494:pharmacology*; D000818:Animals; D001566:Benzocaine / Q000494:pharmacology; D004594:Electrophysiology / Q000379:methods; D005260:Female; D006734:Horse Diseases / Q000235:genetics*; D006736:Horses; D006947:Hyperkalemia / Q000235:genetics / Q000662:veterinary*; D066298:In Vitro Techniques; D008012:Lidocaine / Q000494:pharmacology; D008564:Membrane Potentials / Q000187:drug effects / Q000502:physiology; D008801:Mexiletine / Q000494:pharmacology; D016297:Mutagenesis, Site-Directed; D009865:Oocytes / Q000502:physiology; D010245:Paralyses, Familial Periodic / Q000235:genetics / Q000662:veterinary*; D017354:Point Mutation; D051381:Rats; D015222:Sodium Channels / Q000187:drug effects / Q000235:genetics* / Q000502:physiology*; D014982:Xenopus laevis
D000779:Anesthetics, Local; D015222:Sodium Channels; D008801:Mexiletine; D008012:Lidocaine; D001566:Benzocaine